Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Discontinued Operations (Tables)

v3.10.0.1
Note 3 - Discontinued Operations (Tables)
 6 Months Ended
Jun. 30, 2018
Notes Tables  
Disposal Groups, Including Discontinued Operations [Table Text Block]
   
June 30
,
2018
    
December 31,
2017
  
Accrued liabilities
   $
—
     $
7,092
  
Liabilities associated with discontinued operations, current
   $
—
     $
7,092
  
   
Three Months Ended
June
30,
    
Six
Months Ended
June
30,
  
   
2018
    
2017
    
2018
    
2017
  
Lymphoseek sales revenue
   $
—
     $
9,663
     $
—
     $
2,926,876
  
Cost of goods sold
    
—
      
24,216
      
—
      
388,408
  
Gross profit
    
—
      
(14,553
)
    
—
      
2,538,468
  
Operating expenses:
                                
Research and development
    
2,453
      
75,196
      
2,453
      
358,729
  
Selling, general and administrative
    
—
      
—
      
—
      
820,203
  
Total operating expenses
    
2,453
      
75,196
      
2,453
      
1,178,932
  
(Loss) income from discontinued operations
    
(2,453
)
    
(89,749
)
    
(2,453
)
    
1,359,536
  
Interest expense
    
—
      
—
      
—
      
(1,718,506
)
Loss before income taxes
    
(2,453
)
    
(89,749
)
    
(2,453
)
    
(358,970
)
Benefit from income taxes
    
515
      
7,373
      
515
      
20,733
  
Loss from discontinued operations
   $
(1,938
)
   $
(82,376
)
   $
(1,938
)
   $
(338,237
)